We saw significant positive correlations between ALYREF and MYCN expression levels (Fig. 1i), as well as ALYREF copy number (Fig. 1j), further supporting ALYREF as a key intermediary in the cooperation between 17q21-ter gain and MYCN-amplification in the malignant neuroblastoma phenotype. Here, ALYREF is linked to neuroblastoma.